Forbion Investor Profile: Portfolio & Exits

Forbion Overview

Investor Type
Venture Capital

Status
Active

Professionals
25

Investments
143

Portfolio
22

Exits
70

Forbion General Information

Description

Founded in 2006, Forbion is a venture capital firm based in Naarden, Netherlands. The firm works closely with entrepreneurs to build life sciences companies with technologies and products designed to transform people's lives. The firm is a signatory to the United Nations Principles for Responsible Investment. Besides financial objectives, the firm selects investments that will positively affect the health and well-being of patients. The firm also operates a joint venture with BioGeneration Ventures, which manages three separate seed and early-stage funds focused on Benelux and Germany

Contact Information

Website

www.forbion.com

Year Founded

2006

Investor Status

Actively Seeking New Investments

Primary Investor Type

Venture Capital

Other Investor Types

Growth/Expansion

Impact Investing

Primary Office

Gooimeer 2-35
1411 DC Naarden
Netherlands

+31 035 000 0000



Forbion Investments (143)

Company Name	Deal Date	Deal Type	Deal Size	Industry	Company Stage	Lead Partner
NewAmsterdam Pharma	14-Jan-2021	Early Stage VC	00000	Drug Discovery	Clinical Trials - General	00000000 00000
00000000 000000000	19-Nov-2020	00000 00000	0000	Drug Discovery	Clinical Trials - General	000000 0000000000 00.0
00000 000000000000	11-Nov-2020	00000 00000	000.00	Drug Discovery	Clinical Trials - General	0000 0000000
0000000	10-Nov-2020	00000 00000	000.00	Drug Discovery	Generating Revenue	000000 0000000000 00.0
000000000	08-Sep-2020	00000 00000	0000	Drug Discovery	Clinical Trials - General	00000 0000000 00
000000000000 00000	25-Aug-2020	0000 00000	000.00	Drug Discovery	Clinical Trials - General	000000 00000000
0000 000000000000	10-Aug-2020	00000 00000	00000	Drug Discovery	Pre-Clinical Trials	0000 0000000
00000000	03-Jun-2020	00000 00000	000.00	Drug Discovery	Clinical Trials - Phase 3	00000-000 000000 00
AM-Pharma	31-Mar-2020	Later Stage VC	00000	Drug Discovery	Clinical Trials - Phase 3	00000-000 000000 00
Azafaros	06-Feb-2020	Early Stage VC	000.00	Drug Discovery	Generating Revenue	000000 00000000

You’re viewing 10 of 143 investments. Get the full list »

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Forbion Exits (70)

Company Name	Exit Date	Exit Type	Exit Size
Inflazome	21-Sep-2020	Merger/Acquisition	00000
0000 000000000000	17-Sep-2020	000	00000
00000 000000000000	09-Sep-2020	000000000000000000
000000000	13-Feb-2020	000000000000000000	00.000
0000 000000	01-Oct-2019	000 00 00000000
000000000 00000000	01-Sep-2019	000000000000000000
000000000 00000000	13-May-2019	000	000.00
0000000 000000	18-Apr-2019	000	0000
Mitralign	12-Mar-2019	Merger/Acquisition
Staten Biotechnology	17-Dec-2018	Merger/Acquisition	00000

You’re viewing 10 of 70 exits. Get the full list »

Forbion Fund Performance

Fund Name	Vintage	Size	Dry Powder	DPI	RVPI	TVPI	IRR

This information is available in the PitchBook Platform. To explore Forbion‘s full profile, request access.

Request a free trial

Forbion Investments by Industry, Year, and Region

Investments by Industry

Investments by Year

Investments by Region

PitchBook’s data visualizations quickly surface an investor’s historical investments—showing a breakdown of activity by industry, year and region.

Request a free trial

Forbion Team (33)

Name	Title	Deals	Funds	Office
Vincent van Houten	Chief Financial Officer & General Partner	0		Naarden, Netherlands
Martien van Osch	Co-Founding Partner & Managing Partner	00	0	Naarden, Netherlands
Geert-Jan Mulder MD	Managing Partner and Co-Founding Partner	00	0	Naarden, Netherlands
Sander Slootweg	Co-Founder & Managing Partner	0	0	Naarden, Netherlands
Holger Reithinger Ph.D	General Partner	00	0	Munich, Germany